Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients
Proteins found in tiny blood particles may help doctors predict which prostate cancer patients will struggle most with a specific radiation therapy, potentially guiding treatment choices.
A prospective study of 100 mCRPC patients receiving 177Lu-PSMA-617 used shotgun proteomics to profile plasma extracellular vesicle proteins alongside PSMA-positive CTC enumeration, identifying PSMA, B7-H3, Trop-2, and STEAP1 as surface-targetable EV proteins correlating with worse overall survival. These liquid biopsy biomarkers show potential for patient stratification in lutetium-PSMA trials and may identify targets for combination therapy.
What the study was
- Study design
- Prospective observational study with shotgun proteomics
- Population
- Metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA-617
- Sample size
- 100
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cell Reports Medicine
Why it surfaced
First systematic EV proteomics study (5,137 proteins) for 177Lu-PSMA-617 outcome prediction in mCRPC; identifies druggable surface targets (B7-H3, Trop-2, STEAP1) alongside PSMA and provides framework for biomarker-driven lutetium trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.